Spondyloarthritis & psoriatic arthritis
Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study
Authors' conclusion
Concurrent tirzepatide and biologic initiation in obese PsA was associated with significantly better patient-reported outcomes, skin disease control, baseline-adjusted joint disease activity and CRP reduction at 6 months.
Study context
- Population
- Obese patients with PsA (body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity), tertiary care rheumatology centres1:2 matched
- Participants
- 31 vs 62
- Exposure
- Tirzepatide initiated concurrently with biologic therapy vs biologics alone
- Tirzepatiden = 31
- Controlsn = 62reference
- Outcome
- Clinical outcomes: MDA, DAPSA low disease activity (≤14), PsAID-12 PASS (≤4), HAQ ≤0.5, PASI ≤1, VAS pain and CRP
- Follow-up
- 6 months
Methodological detailspropensity score-matched 1:2 on BMI, disease duration, DAPSA and Psoriasis Area and Severity Index (PASI), prospective enrolment of tirzepatide patients; historical controls (2021-2025), tertiary care rheumatology centres, ANCOVA adjusted for baseline and mixed (time × group) model for continuous outcomes
- Propensity score-matched 1:2 on BMI, disease duration, DAPSA and PASI
- Prospective enrolment of tirzepatide patients; historical controls (2021-2025)
- Tertiary care rheumatology centres
- ANCOVA adjusted for baseline and mixed (time × group) model for continuous outcomes
Main finding
As reported in the abstract
PsAID-12 PASS (≤4)
PsAID-12 PASS achieved, tirzepatide + biologic vs biologic alone (controls)
48% vs 21%
OR 3.44, 95% CI 1.38 to 8.63p=0.009
Observational data: associations, not effects.
Further findings
HAQ ≤0.5 · 6 months
- HAQ ≤0.5 achieved, tirzepatide + biologic vs biologic alone (controls)
- 42% vs 18% (OR 3.27, 95% CI 1.26 to 8.44, p=0.022)
PASI ≤1 · 6 months
- PASI ≤1 achieved, tirzepatide + biologic vs biologic alone (controls)
- 74% vs 52% (OR 2.59, 95% CI 1.03 to 6.56, p=0.045)
BMI change · 6 months
- Greater BMI reduction in the tirzepatide group vs controls
- −2.9±2.0 vs +0.4±1.2 kg/m², p<0.001
C reactive protein (CRP) · 6 months
- Lower CRP in the tirzepatide group vs controls
- 4.2±3.8 vs 7.7±3.0 mg/L, p<0.001
Baseline-adjusted ANCOVA and mixed (time × group) model · 6 months
- Significant 6-month differences in favour of tirzepatide for BMI, CRP, PsAID-12 and DAPSA; significant time × group interaction for BMI, CRP and PsAID-12
Original publication
Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study. RMD Open. Published 30 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →